<DOC>
	<DOCNO>NCT01248000</DOCNO>
	<brief_summary>Positron Emission Tomography ( PET ) represent step forward definition response therapy patient Hodgkin Lymphoma ( HL ) . In particular use PET early assessment response describe important tool predict risk disease progression . As data available support use early assessment response adapt modify subsequent treatment , use PET limit patient enrolled clinical trial . Irrespective recommendation PET scan include current management patient HL baseline , mid treatment , end treatment , follow-up . So far study perform verify PET currently use clinical set assess result PET scan use support treatment clinical decision .</brief_summary>
	<brief_title>The Use FDG-PET Patient With Hodgkin Lymphoma : Population Based Study From Northern Italy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>1 . Histologically confirm classical Hodgkin lymphoma accord current World Health Organisation Classification ( nodular sclerosis , mixed cellularity , lymphocyte rich , lymphocyte deplete ) . 2 . Clinical stage IIV . 3 . No previous chemotherapy , radiotherapy investigational drug HL . 1 . None .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>FDG-PET</keyword>
	<keyword>prognostic factor</keyword>
	<keyword>clinical trial</keyword>
</DOC>